
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech's strong financial position is underscored by approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables as of the end of Q3 2025, positioning the company well for future investments and developments. The company's transition towards becoming a fully integrated oncology company, coupled with an array of diverse pipeline catalysts projected for 2026, presents significant potential for upside opportunities. Additionally, promising data from clinical trials, particularly regarding the effectiveness of BioNTech's therapies, strengthens the outlook for the company's ability to sustain growth and deliver value to shareholders despite declines in COVID-19 vaccine revenues.
Bears say
BioNTech is facing a sustained decline in COVID-related revenues, with projections indicating an 18% decrease in 2025 and a further reduction anticipated in subsequent years, which may hinder cash flow for ongoing R&D initiatives. Manufacturing challenges related to personalized therapeutics, characterized by longer production cycles, may limit the company's ability to capitalize on anticipated cancer therapies. Furthermore, the company presents multiple risks, including potential negative data from their pipeline candidates and various operational uncertainties, collectively contributing to a negative outlook on future revenue generation.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares